Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Manganese API Manufacturers & Suppliers
3 verified results
Commercial-scale Suppliers
All certificates
Employees: 500
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Manganese | CAS No: 7439-96-5 | GMP-certified suppliers
A medication that supplements intravenous Total Parenteral Nutrition to maintain plasma manganese levels and prevent deficiency symptoms in patients requiring parenteral nutritional support.
Therapeutic categories
Primary indications
- Indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN)
- Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms
Product Snapshot
- Manganese is available in multiple formulation types including injectable solutions, oral tablets, capsules, powders, and liquids designed for intravenous, oral, and cutaneous administration
- It is primarily used as a supplement in intravenous solutions for Total Parenteral Nutrition (TPN) to maintain plasma levels and prevent manganese deficiency
- Manganese is approved and marketed as a nutraceutical in key regulatory markets such as the US and Canada
Clinical Overview
Clinically, manganese is indicated as a supplement in intravenous solutions used for Total Parenteral Nutrition (TPN). Supplementation aims to maintain adequate plasma manganese levels, preventing depletion of endogenous stores and subsequent deficiency symptoms in patients unable to obtain sufficient nutrition through oral or enteral routes.
The pharmacodynamics and precise mechanism of action of manganese as an isolated element in the human body are not fully detailed; however, its biological role is largely attributed to its function as a cofactor in enzymatic reactions that participate in amino acid, cholesterol, glucose, and carbohydrate metabolism, as well as in antioxidant processes involving superoxide dismutase.
Absorption of manganese occurs primarily via the gastrointestinal tract when administered orally, with subsequent distribution predominantly to the liver, pancreas, kidneys, and bone. Manganese exhibits relatively complex absorption and excretion dynamics, including biliary excretion. Intravenous administration bypasses gastrointestinal absorption, allowing direct replenishment of systemic levels.
Safety considerations for manganese center on its narrow therapeutic window. Excessive manganese exposure, particularly in occupational or environmental settings or via inadvertent overdose, is linked to manganism—a neurotoxic condition characterized by dopaminergic neuronal death and parkinsonian-like motor symptoms. Therefore, careful monitoring of plasma manganese levels is recommended during TPN use to avoid accumulation and toxicity.
Currently, manganese is approved for use as a nutraceutical element in TPN formulations, with no specific proprietary brands universally recognized due to its role as an elemental micronutrient rather than a proprietary pharmaceutical agent.
For pharmaceutical API sourcing, ensuring the manganese supply meets pharmacopeial standards for purity, batch-to-batch consistency, and absence of toxic contaminants is critical. Manganese APIs should comply with relevant quality guidelines for elemental impurities and trace metals, maintaining suitability for intravenous administration in parenteral nutrition formulations.
Identification & chemistry
| Generic name | Manganese |
|---|---|
| Molecule type | Small molecule |
| CAS | 7439-96-5 |
| UNII | H6EP7W5457 |
| DrugBank ID | DB06757 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial | Humans | |
| Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial | Humans | |
| TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 | Humans |
Formulation & handling
- Manganese is a small molecule API available in both oral and intravenous injectable formulations.
- The compound does not exhibit peptide or biologic characteristics, simplifying its handling and formulation.
- Formulations may require attention to solution stability for intravenous administration and appropriate coating or matrix for controlled oral release forms.
Regulatory status
| Lifecycle | The active pharmaceutical ingredient is currently under patent protection in the United States until July 1, 2041, indicating a mature market stage with exclusivity maintained in both the US and Canada. Generic competition may be limited until patent expiry. |
|---|
| Markets | Canada, US |
|---|
Supply Chain
| Supply chain summary | The manufacturing and supply landscape for Manganese includes multiple originator companies producing branded multivitamin and mineral formulations, with a focus on the Canadian and US markets. Branded products are well-represented in these regions, covering a range of multisupplement formulations. The existing patent protection until 2041 indicates limited generic competition at present, with potential for future entry post-expiry. |
|---|
Manganese is a type of Means in metabolic disorders
The pharmaceutical API subcategory of means in metabolic disorders refers to a group of active pharmaceutical ingredients (APIs) that are utilized in the treatment of various metabolic disorders. Metabolic disorders are medical conditions that involve disruptions in the normal metabolic processes of the body, such as those related to glucose metabolism, lipid metabolism, or hormone regulation.
The means in metabolic disorders APIs encompass a diverse range of compounds that target specific pathways or enzymes involved in metabolic regulation. These APIs play a crucial role in managing conditions like diabetes, obesity, hyperlipidemia, and hormonal imbalances. They are often incorporated into medications designed to improve metabolic function and restore the balance of key biomolecules in the body.
Common APIs in this subcategory include biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose co-transporter 2 (SGLT2) inhibitors. These APIs exert their effects through various mechanisms such as enhancing insulin sensitivity, increasing insulin secretion, reducing glucose production, and promoting weight loss.
The development of means in metabolic disorders APIs involves extensive research and rigorous testing to ensure their efficacy, safety, and compatibility with existing treatment regimens. Pharmaceutical companies collaborate with researchers and regulatory authorities to conduct clinical trials and obtain necessary approvals before these APIs can be integrated into commercial medications.
In summary, means in metabolic disorders APIs are a vital component of pharmaceutical interventions aimed at managing metabolic disorders. By targeting specific metabolic pathways, these APIs contribute to improving patient outcomes and enhancing their overall quality of life.
Manganese (Means in metabolic disorders), classified under Metabolic Bone Disease Agents
Metabolic Bone Disease Agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are specifically designed to treat and manage conditions related to the bones and their metabolism. These agents play a crucial role in the treatment of various metabolic bone diseases, including osteoporosis, Paget's disease, and rickets.
The primary function of Metabolic Bone Disease Agents is to regulate bone remodeling and maintain bone health. They achieve this by targeting specific pathways involved in bone metabolism, such as osteoclast and osteoblast activity, calcium regulation, and vitamin D metabolism.
These APIs are commonly used in the development of medications, including oral tablets, injectables, and topical formulations, for the effective treatment of metabolic bone diseases. They are carefully formulated to optimize their pharmacokinetic and pharmacodynamic properties, ensuring maximum efficacy and minimal side effects.
Metabolic Bone Disease Agents encompass a range of substances, including bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, and vitamin D analogs. These APIs act through different mechanisms to address specific aspects of bone health, such as inhibiting bone resorption, promoting bone formation, or regulating calcium levels.
In conclusion, Metabolic Bone Disease Agents are a vital category of pharmaceutical APIs used in the development of medications for the treatment and management of various metabolic bone diseases. These agents target specific pathways involved in bone metabolism to regulate bone remodeling, enhance bone health, and alleviate the symptoms associated with these conditions.
Manganese API manufacturers & distributors
Compare qualified Manganese API suppliers worldwide. We currently have 3 companies offering Manganese API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Acta minerals | Producer | Netherlands | Netherlands | BSE/TSE, CoA, GMP, MSDS | 67 products |
| DNS Fine Chemicals | Producer | India | India | CoA | 8 products |
| Jost Chemical | Producer | United States | United States | CoA, USDMF | 14 products |
When sending a request, specify which Manganese API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Manganese API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
